Core Insights - The trend of Chinese companies listing in Singapore is experiencing a structural increase, breaking a decade-long stagnation where only 8 Chinese firms were listed on the Singapore Exchange [1][2] - Factors driving this trend include policy support, market adaptation, and strategic needs, with local Southeast Asian investors becoming increasingly important for A-share companies seeking secondary listings [4][6] Group 1: Recent Developments - Since the second half of 2025, companies like Kangji Pharmaceutical and Xiehe New Energy have successfully completed their listings in Singapore, with several others expressing intentions to follow suit [1][2] - The Southbound A500 Index ETF has also made its debut in Singapore, marking the first time A-share core assets have accessed the Singapore market through financial products [2][3] Group 2: Market Dynamics - The Singapore Exchange has optimized its secondary listing framework, reducing the approval cycle to approximately six to eight weeks, and offers various incentives for companies, including listing grants of up to 2 million SGD (approximately 11 million RMB) [5][6] - The market structure in Singapore is seen as advantageous for certain types of Chinese companies, providing unique opportunities to attract Southeast Asian institutional investors [5][6] Group 3: Future Outlook - Industry experts express a generally positive outlook for the continued rise of A-share companies listing in Singapore, aligning with Singapore's financial market development plans [8] - The recent increase in liquidity in Singapore's secondary market has shifted market expectations positively, with the Straits Times Index showing a 28.8% increase over the past year [8]